Ensign Peak Advisors Inc Has $6.47 Million Position in Illumina, Inc. (NASDAQ:ILMN)

Ensign Peak Advisors Inc cut its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 6.7% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 61,953 shares of the life sciences company’s stock after selling 4,450 shares during the quarter. Ensign Peak Advisors Inc’s holdings in Illumina were worth $6,467,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Trivant Custom Portfolio Group LLC raised its stake in shares of Illumina by 166.7% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock valued at $27,000 after buying an additional 125 shares in the last quarter. Versant Capital Management Inc lifted its stake in Illumina by 292.9% during the second quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock worth $34,000 after purchasing an additional 246 shares during the period. Industrial Alliance Investment Management Inc. acquired a new stake in Illumina during the second quarter valued at approximately $34,000. Massmutual Trust Co. FSB ADV boosted its holdings in Illumina by 86.8% during the first quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock valued at $39,000 after purchasing an additional 132 shares in the last quarter. Finally, Ables Iannone Moore & Associates Inc. bought a new stake in shares of Illumina in the 4th quarter valued at approximately $56,000. 89.42% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on ILMN. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $242.00 price target on shares of Illumina in a research note on Wednesday, August 14th. Robert W. Baird upped their target price on shares of Illumina from $119.00 to $124.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. Citigroup increased their target price on shares of Illumina from $140.00 to $155.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Scotiabank reduced their price target on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating on the stock in a research report on Thursday, August 15th. Finally, Jefferies Financial Group initiated coverage on shares of Illumina in a report on Monday, June 3rd. They set a “hold” rating and a $115.00 price objective for the company. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $151.05.

Illumina Price Performance

Shares of ILMN stock opened at $126.15 on Thursday. The firm’s 50 day moving average price is $125.59 and its two-hundred day moving average price is $120.38. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86 and a current ratio of 1.11. Illumina, Inc. has a 52-week low of $89.00 and a 52-week high of $148.19. The stock has a market cap of $20.10 billion, a PE ratio of -15.48 and a beta of 1.15.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, August 6th. The life sciences company reported $0.36 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.24. The business had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. The firm’s quarterly revenue was down 5.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.32 earnings per share. As a group, analysts forecast that Illumina, Inc. will post 3.63 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.